How to overcome challenges in developing & launching most promising vaccine candidates and achieve a competitive advantage in attractive markets? What  are the strategies of the industry, payers, governments & regulators to be prepared for the next pandemic influenza?

Reveal the most powerful tools to improve vaccine quality, safety, compliance, costs, supply and speed. Understand how to reach the approval and fit in the regulatory background. Be a part of the interactive workshop on Accelerated Vaccine Introduction to achieve excellence in time-to-market. Explore the leading trends in the industry and how to walk through the whole Vaccine Value Chain successfully.

 

Leading Pharma companies will share their experiences & achievements in conducting clinical trials. Learn from the best practices on the pathway from production to procurement. Gain first hand information on financing strategies and discuss how to make vaccine development lucrative. Maximize vaccine availability and affordability through strategic collaborations.
 

We bring you the senior vaccine industry experts to benchmark, how successful they are in utilizing the full potential of vaccine markets.

 

 

PRE-CONFERENCE WORKSHOP SESSIONS - 23th of February
 
Several workshops during this day will provide an interactive platform designed to assist participants in acquiring practical skills and knowledge about the areas covered. All presenters are industry professionals, with extensive experience. The sessions are structured in a way to provide a useful experience underlined by real life case studies and lively benchmarking discussions.

 

WORKSHOP SESSION #1: Accelerating Process Development – Do it right from the beginning

 

WORKSHOP SESSION #2: Best practices in proof-of concept clinical trials and vaccine conditioning – Continue with the goal in mind

 

WORKSHOP SESSION #3: Vaccine manufacturing challenges – A vision for the future

 

• Dr Philip Dormitzer, Head of Viral Advanced Programs Global Program Team, U.S.
• Novartis Vaccines
• Gerd Zettlmeissl, Chief Executive Officer, Austria
• Intercell AG
• Ed Geuns, Head of Global Regulatory Affairs Liaison Vaccines, Netherlands
• Abbott Biologicals B.V.
• Danilo Casimiro, Director of Viral Vaccine Research, U.S.
• Merck & Co.
• Benedikt Timmerman, Chief Executive Officer, France
• Genticel
• Dr Farshad Guirakhoo, Senior Director of External R&D, France
• Sanofi Pasteur
• Dr Mats Lundgren, Head of Vaccine Manufacturing Technology R&D, Sweden
• GE Healthcare
• Dr Bram Palache, Global Governmental Affairs Director, Netherlands
• Abbott Biologicals B.V.
• Dr Annie Van Broekhoven, Vice President Biologicals, Belgium
• Innogenetics
• Bernd Eisele, Chief Executive Officer, Germany
• Vakzine Projekt Management Gmbh
• Dr Satish D. Ravetkar, Senior Director, India
• Serum Institute of India
• Michael Kreuze, Principal Engineer, U.S.
• Pfizer
• Dr Jacqueline Shea, General Manager, UK
• Oxford-Emergent Tuberculosis Consortium Ltd

 

Special Contribution from Associations:

 

• Michel Zaffran, Senior Adviser WHO & Director,  Project Optimize, Switzerland
• WHO
• Dr Hansi Dean, Director New Alliances and Initiatives, R&D, U.S.
• International Aids Vaccine Initiativ
• Dr Mansour Yaich, Vaccine Development Director, France
• PATH

 

Next Generation Vaccines 2011 Expert Advisory Board:

 

• Dr Joe Cohen, GSK Bio, Belgium
  VP Vaccines for emerging diseases & HIV
• Dr Philip Dormitzer, Novartis Vaccines, U.S.
  Head of Viral Advanced Programs Global Project Team
• Dr Agnes Hoffenbach, Sanofi Pasteur, France
  Head of Influenza R&D
• Dr Mats Lundgren, GE Healthcare, Sweden
  Head of Vaccine Manufacturing Technology R&D
• Benedikt Timmerman, Genticel, France
  Chief Executive Officer
• Michel Zaffran, WHO, Switzerland
  Senior Adviser WHO & Director, Project Optimize
• Jon Pearman, GAVI Alliance, Switzerland
  Head of Accelerated Vaccine Introduction
• Bernd Eisele, Vakzine Projekt Management Gmbh, Germany
  Chief Executive Officer
• Christian Herzog,Crucell, Switzerland
  Senior Director Medical Affairs
• Dr Geoffrey Evans, HRSA, U.S.
  Head of Vaccine Injury Compensation Program

Great thanks to the Advisory Board who helped to bring new, innovative content to you this year.

---

 

If you are interested in providing further input to the programme or would like to suggest a Speaker/Panelist, please contact victoria.szoboszlai@jacobfleming.com

 

---

 

 

• Exploring the future potential of the vaccine market
• Latest developments in the prophylactic and the therapeutic segment
• Optimizing pre-clinical & clinical trials performance
• Managing challenges in launching new vaccine candidates
• Achieving vaccine manufacturing excellence
• Revealing best practices in vaccine distribution & delivery
• Obtaining funding & financing for vaccines
• Establishing industry partnerships
• Critical insights into preparations for the next pandemic influenza
• Providing routine immunization on a large scale

 

CEOs, CSOs of Pharmaceutical, Biotechnological and Healtchcare Companies,
Heads of Medical Affairs, R&D, Clinical Development, Regulatory affairs, Scientific affairs, Quality Assurance, Product Safety, Manufacturing, Supply Chain, Cold Chain, Delivery, Business Development

 

From:

CROs, CMOs, Equipment Manufacturers & Technology Provider Companies, Drug Delivery & Discovery Companies, Non Governmental Organizations, Public Health Organizations, Strategic Alliances, Investment banks, Private Equity Firms, Management Consultants